Homepage Thermo Fisher Scientific newsroom

New Thermo Scientific Cascadion SM Clinical Analyzer with 25-Hydroxy Vitamin D Assay and Immunosuppressants Panel Available in Australia and New Zealand

Announcement posted by Thermo Fisher Scientific 21 Apr 2021

Scoresby, Australia, April 21, 2021 -- Thermo Fisher Scientific, the world leader in serving science, today announced that its Thermo Scientific Cascadion SM Clinical Analyzer is now commercially available in Australia and New Zealand with the Cascadion SM 25-Hydroxy Vitamin D assay and Cascadion SM Immunosuppressants Panel. Designed to deliver accurate, traceable measurements of vitamin D2 (ergocalciferol) and D3 (cholecalciferol), the 25-Hydroxy Vitamin D serum assay reports total vitamin D results alongside its components. Clinical laboratories can also access the SM Immunosuppressants Panel which enables the simultaneous testing of cyclosporine A, everolimus, sirolimus and tacrolimus from a single whole blood sample aspiration using gold standard liquid chromatography.

Incorporating sample processing, LC separation and MS detection capabilities in a single solution, the Cascadion system is fully automated and enables load-up and walkaway sample management, eliminating the need for multiple connected components. The system offers end-to-end automation that is easy to use by any qualified laboratory personnel with minimal training, thus streamlining and optimizing the analytical process.

The Cascadion system analyzes samples directly from qualified primary blood collection tubes. Additionally, both the Cascadion SM 25-Hydroxy Vitamin D Assay and Cascadion SM Immunosuppressants Panel incorporates fully barcoded components, all traceable to a specific result.

“LC-MS/MS has by tradition been a sophisticated technology, requiring specialised knowledge and significant hands-on time for clinical labs increasing their time to deliver critical results. Many clinical pathology settings in Australia and New Zealand have already adopted LC-MS/MS technology, but are constrained by efficiency with manual and disjointed workflow.” explains Sam Spanswick, Portfolio Leader - Clinical Diagnostics & Healthcare, Thermo Fisher Scientific. “However by automating the gold standard LC-MS/MS technology, using the Cascadion SM Clinical Analyzer, clinical labs are now able to transform their clinical workflows, providing enhanced workflow efficiency and regulatory compliance, reducing staff and budget constraints and providing a cost-effective solution without the need for extensive technical expertise”

Domenic Stranieri, Vice President and General Manager, ANZ, Thermo Fisher Scientific, commented on the launch: “We are delighted to be launching the Cascadion SM Clinical Analyzer, 25-Hydroxy Vitamin D Assay and Immunosuppressants Panel into the clinical diagnostic market in Australia and New Zealand. With no other automated LC-MS/MS system on the market for clinical diagnostics, we are excited to see how this revolutionary new system can transform clinical labs.”

For more information about the Cascadion SM Clinical Analyzer and its assays, please visit www.thermofisher.com/cascadion

About Thermo Fisher Scientific 
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivalled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com